Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-Pol3026
- Development stage
- Preclinical
- Lead developer
- SCK CEN
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
177Lu-DOTA-Pol3026 is a preclinical-stage therapeutic radiopharmaceutical (targeted radionuclide therapy) being developed by the Belgian Nuclear Research Centre (SCK CEN) and the University of Liège for the treatment of glioblastoma. It consists of the beta-hairpin peptidomimetic CXCR4 antagonist POL3026 conjugated to the chelator DOTA and radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). 177Lu-DOTA-Pol3026 selectively binds to C-X-C chemokine receptor type 4 (CXCR4), which is highly expressed in glioblastoma and glioblastoma cancer stem cells, delivering localized ionizing radiation to induce DNA double-strand breaks and tumor cell apoptosis.
- Other names
- [177Lu]Lu-DOTA-POL3026
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on 177Lu-DOTA-Pol3026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-Pol3026.